Teleflex Incorporated (NYSE:TFX)‘s stock had its “buy” rating reaffirmed by equities research analysts at Barclays PLC in a research note issued on Monday.

The analysts wrote, “Epizyme, Inc. announced today that it has expanded its clinical collaboration with Genentech, a member of the Roche Group. Under the new agreement, Tazemetostat administered in combination with atezolizumab (Tecentriq) will be evaluated in a phase Ib/II clinical study for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer (NSCLC).””

A number of other research analysts also recently issued reports on the company. Deutsche Bank AG boosted their price objective on Teleflex from $192.00 to $213.00 and gave the company a “buy” rating in a research note on Wednesday, March 15th. Needham & Company LLC started coverage on Teleflex in a research note on Monday, March 6th. They set a “buy” rating and a $221.00 price objective for the company. Zacks Investment Research downgraded Teleflex from a “buy” rating to a “hold” rating in a research note on Saturday, May 20th. Jefferies Group LLC reiterated a “hold” rating on shares of Teleflex in a research note on Monday, March 27th. Finally, Leerink Swann boosted their price objective on Teleflex from $215.00 to $220.00 and gave the company a “market perform” rating in a research note on Friday, June 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $217.00.

Teleflex (TFX) traded up 0.31% during mid-day trading on Monday, hitting $206.74. 36,422 shares of the stock traded hands. Teleflex has a one year low of $136.53 and a one year high of $211.21. The company has a 50 day moving average price of $200.28 and a 200-day moving average price of $184.94. The stock has a market capitalization of $9.30 billion, a PE ratio of 42.91 and a beta of 1.05.

Teleflex (NYSE:TFX) last announced its quarterly earnings data on Thursday, May 4th. The medical technology company reported $1.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.69 by $0.11. The company had revenue of $487.90 million during the quarter, compared to the consensus estimate of $472.81 million. Teleflex had a return on equity of 16.17% and a net margin of 11.75%. The firm’s revenue was up 14.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.52 EPS. Equities analysts anticipate that Teleflex will post $8.16 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 15th. Shareholders of record on Monday, May 15th were paid a $0.34 dividend. The ex-dividend date of this dividend was Thursday, May 11th. This represents a $1.36 annualized dividend and a yield of 0.66%. Teleflex’s payout ratio is 28.22%.

TRADEMARK VIOLATION WARNING: “Teleflex Incorporated (TFX) Earns “Buy” Rating from Barclays PLC” was reported by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/06/26/teleflex-incorporated-tfx-earns-buy-rating-from-barclays-plc.html.

In other Teleflex news, Director Stephen K. M.D. Klasko sold 5,200 shares of the company’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $193.56, for a total value of $1,006,512.00. Following the completion of the transaction, the director now directly owns 12,880 shares in the company, valued at approximately $2,493,052.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gretchen R. Haggerty purchased 1,000 shares of the company’s stock in a transaction on Wednesday, June 21st. The stock was acquired at an average price of $203.82 per share, with a total value of $203,820.00. Following the completion of the purchase, the director now directly owns 1,760 shares in the company, valued at $358,723.20. The disclosure for this purchase can be found here. Insiders sold a total of 10,146 shares of company stock valued at $1,996,554 over the last 90 days. 2.39% of the stock is currently owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Asset Planning Services Ltd. acquired a new position in Teleflex during the first quarter valued at $116,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in Teleflex during the first quarter valued at $155,000. OLD Mutual Customised Solutions Proprietary Ltd. increased its position in Teleflex by 200.0% in the first quarter. OLD Mutual Customised Solutions Proprietary Ltd. now owns 900 shares of the medical technology company’s stock valued at $174,000 after buying an additional 600 shares during the last quarter. Letko Brosseau & Associates Inc. acquired a new position in Teleflex during the first quarter valued at $213,000. Finally, Independence Advisors LLC acquired a new position in Teleflex during the first quarter valued at $215,000. Institutional investors and hedge funds own 93.33% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Analyst Recommendations for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.